Compound Profile
Pinealon: Where the EDR Tripeptide Has Been Tested
Published: August 25, 2026
TL;DR
Pinealon has a compact research record that moves from cultured cells to two rodent models. Cell studies examined oxidative stress, necrotic cell death, intracellular localization, and nucleic-acid interactions. A prenatal-hyperhomocysteinemia rat study used 10 micrograms/kg intraperitoneally, while a 5xFAD mouse study used 400 micrograms/kg intraperitoneally once daily for two months and reported CA1 dendritic-spine density 11% higher in males and 12% higher in females than in saline controls. These findings define where EDR has been tested. They do not establish human cognitive efficacy.
Curo lists this material as Pinealon 10 mg in the research peptide catalogue. That 10 mg is a vial size and has nothing to do with the per-kilogram amounts the animal papers used. Lot documents are searchable through the COA library, and the guide to matching a certificate to its lot covers the check itself.
The first tests were cell systems
The 2011 oxidative-stress study used three different systems: cultured cerebellar granule cells, neutrophils, and PC12 cells. Investigators added Pinealon to each and reported concentration-dependent reductions in reactive oxygen species associated with oxidative stress. Propidium iodide measurements also showed less necrotic cell death. The same work described delayed ERK1/2 activation and changes in cell-cycle processes after the peptide was added. These are all findings from cultured-cell experiments, not observations from intact animals or people.
Across all three systems, investigators measured reactive oxygen species and propidium-iodide-marked necrotic cell death while also following ERK1/2 activation and cell-cycle processes. The recurring findings were lower stress-associated reactive oxygen species and less necrosis, but every endpoint remained inside a cell-culture experiment. The response was described as concentration-dependent. The individual culture concentrations are not reported in the accessible record.
A second 2011 experiment asked where labelled short peptides went inside cells. Fluorescein-labelled Pinealon produced signal in the cytoplasm, nucleus, and nucleolus of HeLa cells. The investigators also reported in vitro interaction with DNA and oligonucleotides. That localization and nucleic-acid work supports hypotheses about how EDR might interact with cellular material. It does not validate a human molecular target or show direct regulation of genes in people, and the accessible record does not give the concentration used in the HeLa-cell work.
Two rodent models used very different study designs
The first in vivo step was a prenatal-hyperhomocysteinemia rat model. Investigators administered Pinealon to maternal rats intraperitoneally at 10 micrograms/kg body weight once daily during the five days before methionine loading. In the offspring, the EDR group showed better spatial orientation and learning measures. Isolated offspring cerebellar neurons also showed lower reactive oxygen species and fewer necrotic cells. The amount, route, timing, and outcomes belong to this specific prenatal rat experiment; they are not research-use guidance.
The later animal study used 5xFAD mice, a model selected for Alzheimer-related research. Investigators administered EDR intraperitoneally at 400 micrograms/kg once daily for two months. Compared with saline-control 5xFAD mice, the EDR group had CA1 dendritic-spine density 11% higher in males and 12% higher in females. The same study used molecular docking to propose possible binding sites in several gene promoters. Both the spine-density result and the docking analysis came from the 5xFAD mouse experiment. The percentage differences are relative findings within that mouse design, not evidence of an established effect in people.
These two models should not be blended into a single dose story. The rat work used 10 micrograms/kg for five days before a defined experimental challenge. The mouse work used 400 micrograms/kg daily for two months. Both used intraperitoneal administration, but neither the amount nor the duration matched. Species, model, timing, endpoints, and study purpose all changed at once.
EDR identity is clear at the compound level
The PubChem record for CID 10273502 identifies Pinealon as Glu-Asp-Arg, or EDR, gives CAS 175175-23-2, and lists "Pinealon acetate salt form" among the synonyms. The neutral parent carries formula C15H26N6O8 and molecular weight 418.40 g/mol.
The FDA UNII Search Service returns no record for PINEALON, and that result does not determine FDA approval or legal status. It means a Pinealon lot cannot be checked by matching the name to a returned UNII. Identity review instead has to stay attached to the exact product label, lot number, material form, and lot-specific analytical result. Curo explains the analytical expectations in its quality and testing standard, alongside the intended-use boundary on the research-use-only page.
This distinction is practical. A catalogue name and size identify what was listed for sale. They do not show that the supplied material is the neutral parent, an acetate form, or the same material used in any paper. Lot-level documentation is what connects a physical item to its stated identity.
The human record comes from older reports
A 2015 unregistered report described combined Pinealon and Vesugen administration in people aged 41 to 83 years with chronic polymorbidity and organic brain syndrome in remission. Its abstract says 32 people, then separately lists 18 men and 12 women, which totals 30. More importantly for compound evaluation, the report used two peptides together, so its observations cannot be assigned specifically to Pinealon.
Another unregistered 2012 occupational report examined 150 lorry drivers and 150 metal-craftsmen controls. Its strongest presented result followed combined Pinealon and Vesugen administration. The combined design again prevents isolation of a Pinealon-specific effect. A ClinicalTrials.gov search for Pinealon returned zero studies on August 25, 2026. Under that name the registry holds no trial and no posted result.
For comparison, follow the Selank review for a peptide from the same Russian research tradition examined in anxiety and cytokine work. The Semax registry review shows how a heavily published Russian compound looks when viewed through US registries.
Common questions
What is the most notable Pinealon result so far?
The clearest quantitative result is the 5xFAD mouse finding: CA1 dendritic-spine density was 11% higher in males and 12% higher in females than in saline-control 5xFAD mice after the study's two-month EDR regimen. It remains a model-specific preclinical result.
Do the cell studies establish Pinealon's mechanism in people?
No. They show lower oxidative-stress-associated markers and necrotic cell death in cultured systems, plus fluorescent localization and in vitro nucleic-acid interactions. They generate mechanism hypotheses but do not establish a validated human target.
Is the 10 mg catalogue item comparable to the animal-study amounts?
No. The catalogue figure is the total listed product size. The animal papers report amounts per kilogram administered under their own experimental designs. Neither converts the catalogue item into a protocol or a known safe human amount.
What should be checked before evaluating a Pinealon lot?
Match the product label and lot number to the batch-specific certificate, then review the stated identity method and result. A catalogue name and product size cannot replace lot-level analytical documentation.